Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
ANIXSAN JOSE, Calif., Feb. 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names (USAN) Council approved "liraltagene...
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
ANIXSAN JOSE, Calif., Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World...
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
ANIX(NASDAQ:ANIX) SAN JOSE, Calif., Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the time of management's presentation at the H.C. Wainwright 27th Annual...
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
ANIXSAN JOSE, Calif., Aug. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 27th Annual Global...
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
ANIXNotice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protection of Breast Cancer Vaccine in China into at least the 2040s SAN JOSE,...
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
ANIXFourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
ANIXNewly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
ANIXDr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr....
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
ANIXAnixa Biosciences To Present e-Poster On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025
ANIXAnixa Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Breast Cancer Vaccine
ANIXD. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
ANIXAnixa Biosciences Receives A Notice Of Allowance From The United States Patent And Trademark Office For A New Patent Application Covering Its Chimeric Antigen Receptor-T Cell Technology
ANIXD. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
ANIXEXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent
ANIXAnixa secures USPTO patent for its breast cancer vaccine using α-lactalbumin, enhancing its IP portfolio and expanding future immunotherapy options.
EXCLUSIVE: Anixa Biosciences Tells Benzinga 'Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach'
ANIXEXCLUSIVE: Anixa Biosciences Tells Benzinga Co. Receives Notice Of Allowance From US Patent And Trademark Office For Patent Covering Breast Cancer Vaccine Technology
ANIXD. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
ANIXEXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines
ANIXAnixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned.
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine
ANIXAnixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.
EXCLUSIVE: Anixa Biosciences Tells Benzinga 'The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2)'
ANIXEXCLUSIVE: Anixa Biosciences Tells Benzinga Co. Receives Notice Of Allowance From USPTO For ovarian Cancer Vaccine
ANIXMaxim Group Initiates Coverage On Anixa Biosciences with Buy Rating, Announces Price Target of $10
ANIXAnixa Biosciences Announces CAR-T Therapy For Ovarian Cancer, Developed With Moffitt Cancer Center
ANIXHC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $7 Price Target
ANIXAnixa Biosciences And Moffitt Cancer Center Receive Approval For Amendment To CAR-T Therapy Clinical Trial Protocol For Ovarian Cancer Treatment
ANIXD. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
ANIXD. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
ANIXHC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $7 Price Target
ANIXAnixa Biosciences Sets November 8 For Public Release Of Phase 1 Breast Cancer Vaccine Data At SITC Annual Meeting
ANIXAnixa Biosciences Begins Treatment Of Fifth Patient In Ovarian Cancer CAR-T Clinical Trial
ANIXAnixa Biosciences' Ovarian Cancer CAR-T Therapy To Be Presented At The Rivkin Center & American Association Of Cancer Research 14th Biennial Ovarian Cancer Research Symposium
ANIX